Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/25/2015 02/26/2015 02/27/2015 03/02/2015 03/03/2015 Date
423.04(c) 419.87(c) 413.84(c) 418.44(c) 412.505(c) Last
764 900 691 046 811 008 614 013 583 677 Volume
+0.57% -0.75% -1.44% +1.11% -1.42% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
03/03 | 09:20amPresentation
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 3 559 M
EBIT 2015 1 546 M
Net income 2015 553 M
Finance 2015 1 725 M
Yield 2015 -
Sales 2016 4 295 M
EBIT 2016 2 046 M
Net income 2016 810 M
Finance 2016 3 058 M
Yield 2016 -
PER 2015 84,24
PER 2016 57,73
EV / Sales 2015 11,6x
EV / Sales 2016 9,29x
Capitalization 42 939 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
02/27 REGENERON PHARMACEUTICALS : Entry into a Material Definitive Agreement (form 8-K..
02/26DJBayer's EYLEA Gets EU Approval for Retinal Vein Occlusion Treatment
02/26 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Receives EU Approval ..
02/26 REGENERON PHARMACEUTICALS : Assigned Patent
02/25 REGENERON PHARMACEUTICALS : NIH-Sponsored Comparative Effectiveness Trial in Dia..
02/23 Canada's Valeant to buy Salix in $10.1 billion deal
02/19 Sanofi names CEO, cites 'capability to unite teams'
02/19 NASDAQ 100 MOVERS : Vip, pcln
More news
Sector news Pharmaceuticals - NEC
08:40p JOHNSON & JOHNSON : Announces Binding Offer from Cardinal Health to Acquire Cord..
07:31p ACTAVIS : Announces Pricing of Public Offering of Senior Notes in Connection wit..
05:52pDJFDA Warns on Low-Testosterone Drugs -- Update
Plus d'actualités du secteur Pharmaceuticals - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF